Victory Capital Management Inc. Has $3.73 Million Stake in ADMA Biologics Inc (NASDAQ:ADMA)

Victory Capital Management Inc. lifted its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 70.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 187,822 shares of the biotechnology company’s stock after purchasing an additional 77,874 shares during the quarter. Victory Capital Management Inc. owned 0.08% of ADMA Biologics worth $3,726,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the stock. B Group Inc. bought a new stake in shares of ADMA Biologics in the 4th quarter valued at approximately $39,231,000. Raymond James Financial Inc. bought a new position in ADMA Biologics during the fourth quarter valued at approximately $19,076,000. Arrowstreet Capital Limited Partnership lifted its stake in ADMA Biologics by 57.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,762,700 shares of the biotechnology company’s stock valued at $47,380,000 after acquiring an additional 1,013,456 shares during the last quarter. Dimensional Fund Advisors LP grew its position in ADMA Biologics by 16.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company’s stock worth $80,065,000 after acquiring an additional 643,661 shares in the last quarter. Finally, Man Group plc increased its stake in shares of ADMA Biologics by 305.5% during the 4th quarter. Man Group plc now owns 745,300 shares of the biotechnology company’s stock worth $12,782,000 after purchasing an additional 561,507 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Lawrence P. Guiheen sold 20,000 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the sale, the director owned 94,830 shares in the company, valued at $1,987,636.80. The trade was a 17.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the transaction, the director directly owned 87,330 shares in the company, valued at $1,767,559.20. The trade was a 69.04% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 464,621 shares of company stock valued at $9,644,269 over the last 90 days. 3.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ADMA shares. Wall Street Zen cut shares of ADMA Biologics from a “hold” rating to a “sell” rating in a report on Friday, May 9th. Raymond James Financial boosted their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a “strong-buy” rating in a research report on Thursday, May 8th.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $18.01 on Monday. The firm has a market capitalization of $4.30 billion, a P/E ratio of 21.19 and a beta of 0.43. The stock has a fifty day moving average price of $18.98 and a two-hundred day moving average price of $18.73. ADMA Biologics Inc has a 52-week low of $10.21 and a 52-week high of $25.67. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The business had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. During the same period in the previous year, the firm earned $0.08 earnings per share. The firm’s revenue was up 40.2% compared to the same quarter last year. As a group, analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.